As the ecosystem around psychedelics in Europe develops, UK-based Clerkenwell Health is cementing itself as a serious player on the continent with the appointment of clinical...
The Multidisciplinary Association for Psychedelic Studies (MAPS) has received funding of $1.5m from Wasana Health in a first-of-its-kind collaboration to accelerate research into MDMA-assisted therapy for...
A new, pooled analysis has found that single-dose, clinical administration of LSD is safe in regards to acute psychological and physical harm in healthy subjects.
The first patient has received a dose of psilocybin in the world’s first trial investigating psilocybin as a treatment for a rare and debilitating headache disorder...
Atai Life Sciences and Introspect Digital Therapeutics will be testing a novel, digital therapeutic approach for patients using ketamine for treatment resistant depression.
Origin Therapeutics is poising for public listing on the Canadian Securities Exchange (CSE).
The company that launched the world’s first psilocybin nasal spray, Silo Wellness, is on a mission to bring healing through psychedelic and functional mushrooms with the...
The End in Mind conference will bring together celebrities, healthcare and psychedelics experts and policy makers to explore the role that psychedelics can play in the...
A new partnership between a Danish and a British startup will lead the way for advancing patient access to medical psychedelics in Europe.
Little Green Pharma has been granted a licence to supply psilocybin from the Western Australia Government Department of Health.
Novel analogues of the psychedelic compound 5-MeO-DMT have shown demonstrable safety in preclinical results.
The first-ever authorised export of GMP-compliant natural psilocybin into the US has been completed.
